WallStSmart

American International Group Inc (AIG)vsDrugs Made In America Acquisition Corp. Ordinary Shares (DMAA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AIG leads profitability with a 11.6% profit margin vs 0.0%. AIG trades at a lower P/E of 13.7x. AIG earns a higher WallStSmart Score of 60/100 (C).

AIG

Buy

60

out of 100

Grade: C

Growth: 2.0Profit: 5.0Value: 7.0Quality: 7.0
Piotroski: 5/9Altman Z: 0.88

DMAA

Avoid

32

out of 100

Grade: F

Growth: 4.3Profit: 3.5Value: 4.0Quality: 4.0
Piotroski: 2/9

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AIG4 strengths · Avg: 8.8/10
Price/BookValuation
1.0x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.229/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.868/10

Growing faster than its price suggests

P/E RatioValuation
13.7x8/10

Attractively priced relative to earnings

DMAA0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

AIG4 concerns · Avg: 2.3/10
Return on EquityProfitability
7.4%3/10

ROE of 7.4% — below average capital efficiency

Revenue GrowthGrowth
-7.2%2/10

Revenue declined 7.2%

EPS GrowthGrowth
-5.6%2/10

Earnings declined 5.6%

Altman Z-ScoreHealth
0.882/10

Distress zone — elevated risk

DMAA4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$355.55M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : AIG

The strongest argument for AIG centers on Price/Book, Debt/Equity, PEG Ratio. PEG of 0.86 suggests the stock is reasonably priced for its growth.

Bull Case : DMAA

DMAA has a balanced fundamental profile.

Bear Case : AIG

The primary concerns for AIG are Return on Equity, Revenue Growth, EPS Growth.

Bear Case : DMAA

The primary concerns for DMAA are Revenue Growth, EPS Growth, Market Cap. A P/E of 55.5x leaves little room for execution misses.

Key Dynamics to Monitor

AIG profiles as a declining stock while DMAA is a value play — different risk/reward profiles.

DMAA is growing revenue faster at 0.0% — sustainability is the question.

AIG generates stronger free cash flow (636M), providing more financial flexibility.

Monitor INSURANCE - DIVERSIFIED industry trends, competitive dynamics, and regulatory changes.

Bottom Line

AIG scores higher overall (60/100 vs 32/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

American International Group Inc

FINANCIAL SERVICES · INSURANCE - DIVERSIFIED · USA

American International Group, Inc., also known as AIG, is an American multinational finance and insurance corporation with operations in more than 80 countries and jurisdictions. The company operates through three core businesses: General Insurance, Life & Retirement, and a standalone technology-enabled subsidiary.

Drugs Made In America Acquisition Corp. Ordinary Shares

FINANCIAL SERVICES · SHELL COMPANIES · USA

Drugs Made In America Acquisition Corp. (DMAA) is a special purpose acquisition company focused on transforming the U.S. pharmaceutical industry through strategic partnerships with innovative firms dedicated to enhancing domestic drug production and distribution. In response to growing concerns over supply chain vulnerabilities, DMAA aims to facilitate the development of more accessible and cost-effective pharmaceuticals, thereby addressing critical market needs. By investing in technological advancements and fostering collaboration within the healthcare sector, DMAA is positioned to play a pivotal role in revitalizing local manufacturing and improving consumer access to essential medications.

Want to dig deeper into these stocks?